Visish M Srinivasan1, Joy Gumin1, Kevin M Camstra2, Dalis E Collins3, Melissa M Chen4, Elizabeth J Shpall5, Brittany C Parker Kerrigan1, Jeremiah N Johnson2, Stephen R Chen6, Juan Fueyo7, Cande Gomez-Manzano7, Frederick F Lang1, Peter Kan1,2. 1. Department of Neurosurgery, Baylor College of Medicine, Houston, Texas. 2. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. 3. Center for Comparative Medicine, Baylor College of Medicine, Houston, Texas. 4. Department of Diagnostic Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. 5. Department of Stem Cell Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. 6. Department of Interventional Radiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas. 7. Department of Neuro-Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Abstract
BACKGROUND: Delta-24-RGD, an oncolytic adenovirus, shows promise against glioblastoma. To enhance virus delivery, we recently demonstrated that human bone marrow-derived mesenchymal stem cells loaded with Delta-24-RGD (hMSC-D24) can eradicate glioblastomas in mouse models. There are no studies examining the safety of endovascular selective intra-arterial (ESIA) infusions of MSC-D24 in large animals simulating human clinical situations. OBJECTIVE: To perform canine preclinical studies testing the feasibility and safety of delivering increasing doses of hMSCs-D24 via ESIA infusions. METHODS: ESIA infusions of hMSC-D24 were performed in the cerebral circulation of 10 normal canines in the target vessels (internal carotid artery [ICA]/P1) via transfemoral approach using commercially available microcatheters. Increasing concentrations of hMSC-D24 or particles (as a positive control) were injected into 1 hemisphere; saline (negative control) was infused contralaterally. Toxicity (particularly embolic stroke) was assessed on postinfusion angiography, diffusion-weighted magnetic resonance imaging, clinical exam, and necropsy. RESULTS: ESIA injections were performed in the ICA (n = 7) or P1 (n = 3). In 2 animals injected with particles (positive control), strokes were detected by all assays. Of 6 canines injected with hMSC-D24 through the anterior circulation, escalating dose from 2 × 106 cells/20 mL to 1 × 108 cells/10 mL resulted in no strokes. Two animals had ischemic and hemorrhagic strokes after posterior cerebral artery catheterization. A survival experiment of 2 subjects resulted in no complications detected for 24-h before euthanization. CONCLUSION: This novel study simulating ESIA infusion demonstrates that MSCs-D24 can be infused safely at least up to doses of 1 × 108 cells/10 mL (107 cells/ml) in the canine anterior circulation using commercially available microcatheters. These findings support a clinical trial of ESIA infusion of hMSCs-D24.
BACKGROUND:Delta-24-RGD, an oncolytic adenovirus, shows promise against glioblastoma. To enhance virus delivery, we recently demonstrated that human bone marrow-derived mesenchymal stem cells loaded with Delta-24-RGD (hMSC-D24) can eradicate glioblastomas in mouse models. There are no studies examining the safety of endovascular selective intra-arterial (ESIA) infusions of MSC-D24 in large animals simulating human clinical situations. OBJECTIVE: To perform canine preclinical studies testing the feasibility and safety of delivering increasing doses of hMSCs-D24 via ESIA infusions. METHODS:ESIA infusions of hMSC-D24 were performed in the cerebral circulation of 10 normal canines in the target vessels (internal carotid artery [ICA]/P1) via transfemoral approach using commercially available microcatheters. Increasing concentrations of hMSC-D24 or particles (as a positive control) were injected into 1 hemisphere; saline (negative control) was infused contralaterally. Toxicity (particularly embolic stroke) was assessed on postinfusion angiography, diffusion-weighted magnetic resonance imaging, clinical exam, and necropsy. RESULTS:ESIA injections were performed in the ICA (n = 7) or P1 (n = 3). In 2 animals injected with particles (positive control), strokes were detected by all assays. Of 6 canines injected with hMSC-D24 through the anterior circulation, escalating dose from 2 × 106 cells/20 mL to 1 × 108 cells/10 mL resulted in no strokes. Two animals had ischemic and hemorrhagic strokes after posterior cerebral artery catheterization. A survival experiment of 2 subjects resulted in no complications detected for 24-h before euthanization. CONCLUSION: This novel study simulating ESIA infusion demonstrates that MSCs-D24 can be infused safely at least up to doses of 1 × 108 cells/10 mL (107 cells/ml) in the canine anterior circulation using commercially available microcatheters. These findings support a clinical trial of ESIA infusion of hMSCs-D24.
Authors: Tuomas Mäkelä; Reijo Takalo; Oiva Arvola; Henri Haapanen; Fredrik Yannopoulos; Roberto Blanco; Lauri Ahvenjärvi; Kai Kiviluoma; Erja Kerkelä; Johanna Nystedt; Tatu Juvonen; Petri Lehenkari Journal: Cytotherapy Date: 2015-01-15 Impact factor: 5.414
Authors: Akira Nakamizo; Frank Marini; Toshiyuki Amano; Asadullah Khan; Matus Studeny; Joy Gumin; Julianne Chen; Stephen Hentschel; Giacomo Vecil; Jennifer Dembinski; Michael Andreeff; Frederick F Lang Journal: Cancer Res Date: 2005-04-15 Impact factor: 12.701
Authors: Phil Hyu Lee; Ji E Lee; Han-Soo Kim; Sook K Song; Hye Sun Lee; Hyo Suk Nam; June-Won Cheong; Yong Jeong; Hae-Jeong Park; Dong Joon Kim; Chung Mo Nam; Jong Doo Lee; Hyun Ok Kim; Young H Sohn Journal: Ann Neurol Date: 2012-07 Impact factor: 10.422
Authors: Raymund L Yong; Naoki Shinojima; Juan Fueyo; Joy Gumin; Giacomo G Vecil; Frank C Marini; Oliver Bogler; Michael Andreeff; Frederick F Lang Journal: Cancer Res Date: 2009-11-17 Impact factor: 12.701
Authors: Naoki Shinojima; Anwar Hossain; Tatsuya Takezaki; Juan Fueyo; Joy Gumin; Feng Gao; Felix Nwajei; Frank C Marini; Michael Andreeff; Jun-Ichi Kuratsu; Frederick F Lang Journal: Cancer Res Date: 2013-01-30 Impact factor: 12.701
Authors: Visish M Srinivasan; Frederick F Lang; Stephen R Chen; Melissa M Chen; Joy Gumin; Jeremiah Johnson; Jan-Karl Burkhardt; Peter Kan Journal: J Neurointerv Surg Date: 2019-11-01 Impact factor: 5.836
Authors: Frederick F Lang; Charles Conrad; Candelaria Gomez-Manzano; W K Alfred Yung; Raymond Sawaya; Jeffrey S Weinberg; Sujit S Prabhu; Ganesh Rao; Gregory N Fuller; Kenneth D Aldape; Joy Gumin; Luis M Vence; Ignacio Wistuba; Jaime Rodriguez-Canales; Pamela A Villalobos; Clemens M F Dirven; Sonia Tejada; Ricardo D Valle; Marta M Alonso; Brett Ewald; Joanna J Peterkin; Frank Tufaro; Juan Fueyo Journal: J Clin Oncol Date: 2018-02-12 Impact factor: 50.717